Brief: Diasorin Sees 2030 Adj EBITDA Margin At 34%-35%
May 20 (Reuters) - DiaSorin SpA DIAS.MI: SEES 2026 REVENUE GROWTH OF 5%-6%, 2026-2030 CAGR OF 6%-8% SEES 2026 ADJUSTED EBITDA MARGIN AT 32%-33%, 2030 AT 34%-35% SEES CUMULATIVE FREE CASH FLOW 2027-2030 AT ABOUT €1 BILLION Further company coverage: DIAS.MI (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 769 66 00;))
Recent news on DiaSorin SpA
See all newsKepler sees European Medtech recovery, starts BioMerieux at 'Buy' as top pick
Brief: Diasorin Receives Us' FDA 510(K) Clearance And Clia Waiver For Liaison Nes Group A Streptococcus (Gas) Assay
Deutsche Bank cuts Diasorin to 'sell', sees company targets as stretched
Italy - Factors to watch on June 5
Italy's DiaSorin jumps after Betaville reports possible takeover interest